Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

Slides:

Advertisements

Similar presentations

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Advertisements

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of a Leukemic Stem Cell Gene Expression.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.

Guido Marcucci, M.D., Michael D. Radmacher, Ph.D., Kati Maharry, M.A.S., Krzysztof Mrózek, M.D., Ph.D., Amy S. Ruppert, M.A.S., Peter Paschka, M.D., Tamara.

NPM1, IDH1/2 and DNAH11 Gene Mutations Can Improve a Prognostic Stratification of Acute Myeloid Leukemia Patients with Normal Karyotype but Not Harboring.

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

EHT, a New Member of the MTG8/ETO Gene Family, Maps on 20q11 Region and Is Deleted in Acute Myeloid Leukemias by Nicola Stefano Fracchiolla, Gualtiero.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia by Michael H. Tomasson,

Gupta V, Tallman MS, Weisdorf DJ

One giant leap for pediatric AMKL

How I treat elderly patients with myeloma

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Saman.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling by.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with.

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Gene expression profiling of pediatric acute myelogenous leukemia

A novel hierarchical prognostic model of AML solely based on molecular mutations by Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

Granulocyte colony-stimulating factor receptor mutations in a patient with acute lymphoblastic leukemia secondary to severe congenital neutropenia by Manuela.

by Giridharan Ramsingh, Meagan A. Jacoby, Jin Shao, Rigoberto E

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

by Gregory H. Underhill, David George, Eric G. Bremer, and Geoffrey S

by William Blum, Sebastian Schwind, Somayeh S

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia by Sarah Bertoli,

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia by Floriana Manodoro, Jacek Marzec, Tracy.

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia by Parvathi Ranganathan, Xueyan Yu, Caroline Na, Ramasamy Santhanam, Sharon Shacham,

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse by Alexander Höllein, Manja Meggendorfer, Frank Dicker,

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes by Kazuaki Yokoyama, Eigo Shimizu, Nozomi.

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB (Alliance)‏ by Gail J. Roboz, Sumithra J. Mandrekar,

Nicholas E. Khan, Philip S. Rosenberg, Blanche P. Alter

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA by Nikola P. Konstandin, Friederike Pastore, Tobias Herold, Annika Dufour,

Impact of somatic and germline mutations on the outcome of systemic mastocytosis by Javier I. Muñoz-González, María Jara-Acevedo, Iván Alvarez-Twose, Jason.

Emerging Importance of Mutational Analysis in Myelodysplastic Syndrome and Acute Myelogenous Leukemia Aaron T. Gerds, Matthew J. Walter, Bart L. Scott

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Volume 17, Issue 4, Pages (April 2010)

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission by Sumithira Vasu, Jessica.

Favorable Outcome in Patients with Acute Myelogenous Leukemia with the Nucleophosmin Gene Mutation Autografted after Conditioning with High-Dose Continuous.

Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia by Heiko Becker, Gabriele Greve, Keisuke Kataoka,

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib. by Richard.

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy by Wyndham H. Wilson, Michael L. Grossbard,

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

Heat map of microRNA microarray expression from the four groups of patients. Heat map of microRNA microarray expression from the four groups of patients.

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML by Jeffrey.

SY-1425 shows similar response in RARA-high AML cell lines to APL

by Jan J. Cornelissen, and Didier Blaise

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML by Ronan T. Swords, Steven Coutre, Michael.

Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.

Presentation transcript:

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, Michael D. Radmacher, Krzysztof Mrózek, Kati Maharry, Heiko Becker, Klaus H. Metzeler, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Maria R. Baer, Jonathan E. Kolitz, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, and Clara D. Bloomfield Blood Volume 118(15):4188-4198 October 13, 2011 ©2011 by American Society of Hematology

Outcome of CN-AML patients 60 years of age or older with respect to MN1 expression. Outcome of CN-AML patients 60 years of age or older with respect to MN1 expression. (A) OS. (B) EFS. Sebastian Schwind et al. Blood 2011;118:4188-4198 ©2011 by American Society of Hematology

Outcome of CN-AML patients 70 years of age or older with respect to MN1 expression and NPM1 mutation status. Outcome of CN-AML patients 70 years of age or older with respect to MN1 expression and NPM1 mutation status. (A) OS. (B) EFS. Sebastian Schwind et al. Blood 2011;118:4188-4198 ©2011 by American Society of Hematology

Outcome of CN-AML patients 60 years of age or older with respect to MN1 expression within the ELN Favorable and ELN Intermediate-I genetic groups. Outcome of CN-AML patients 60 years of age or older with respect to MN1 expression within the ELN Favorable and ELN Intermediate-I genetic groups. (A) OS. (B) EFS. Sebastian Schwind et al. Blood 2011;118:4188-4198 ©2011 by American Society of Hematology

Heat map of the derived gene expression signature associated with MN1 expression in the group of CN-AML patients 60 years of age or older. Heat map of the derived gene expression signature associated with MN1 expression in the group of CN-AML patients 60 years of age or older. The patients are ordered from left to right by increasing expression of MN1. Expression values of the probe sets are represented by color: blue represents expression less than the median value for the given probe set; and red, expression greater than the median value for the given probe set. Up- and down-regulated genes that are mentioned in the text are indicated along the side. Sebastian Schwind et al. Blood 2011;118:4188-4198 ©2011 by American Society of Hematology

Heat map and table of the derived microRNA expression signature associated with MN1 expression in the group of CN-AML patients 60 years of age or older. Heat map and table of the derived microRNA expression signature associated with MN1 expression in the group of CN-AML patients 60 years of age or older. (A) Heat map of the derived microRNA expression signature associated with MN1 expression in the group of CN-AML patients 60 years of age or older. The patients are ordered from left to right by increasing expression of MN1. Expression values of the probe sets are represented by color: blue represents expression less than the median value for the given probe; and red, expression greater than the median value for the given probe. Up- and down-regulated genes and microRNAs are indicated along the side. (B) Tables showing fold changes of the microRNAs that form the signature with corresponding fold changes. Sebastian Schwind et al. Blood 2011;118:4188-4198 ©2011 by American Society of Hematology